Tender detail
Non-exclusive discount agreement for fentanyl nasal spray medicines
Summary
DAK-Gesundheit intends to conclude non-exclusive discount agreements with interested pharmaceutical companies for medicines containing fentanyl, exclusively in nasal spray form (ATC N02AB03). The agreements are scheduled to run from 1 January 2027 to 31 December 2028, with one optional 12-month extension, and will end automatically if an exclusive agreement takes effect earlier.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.